



Medical Coverage Policy

Effective Date5/15/2024

Next Review Date5/15/2025

Coverage Policy Number..... 0287

Cell-Based Therapy for Cardiac and Peripheral Arterial Disease

Table of Contents

Overview	2
Coverage Policy	2
General Background.....	2
Medicare Coverage Determinations	9
Coding Information	9
References.....	10
Revision Details.....	14

Related Coverage Resources

- [Donor Lymphocyte Infusion and Hematopoietic Progenitor Cell \(HPC\) Boost](#)
- [Percutaneous Revascularization of the Lower Extremities in Adults](#)
- [Stem Cell Transplantation: Blood Cancers](#)
- [Stem Cell Transplantation: Solid Tumors](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted

for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses cell-based therapy using several cell types, proposed as a method to treat heart damage or peripheral arterial disease.

Coverage Policy

Transplantation of cells into the myocardium is considered experimental, investigational or unproven for ANY indication.

Autologous intra-arterial or intra-muscular bone marrow cell transplantation is considered not medically necessary for peripheral arterial disease and other occlusive conditions.

General Background

Cell-Based Therapy for Treatment of Damaged Myocardium

Cardiovascular-oriented research of cell-based therapy has largely been focused on myocardial repair, with particular emphasis on replacement and/or restoration of the damaged myocardium. Transplantable cell types being researched include skeletal myoblasts, bone marrow mononuclear cells (BM-MNC), hematopoietic stem cells (HSC), endothelial progenitor cells (EPC), mesenchymal stem cells (MSC), and pluripotent stem cell (PSC)-derived cardiomyocytes (CM) (PSC-CM).

Skeletal myoblasts are tissue-specific stem cells. Immature myoblasts contained in skeletal muscle can fuse with surrounding myoblasts or with damaged muscle fibers to regenerate functional skeletal muscle. Mesenchymal stem cells and hematopoietic stem cells have the capacity to differentiate into any type of cell, depending on their microenvironment. As they mature, they can acquire all the characteristics of the target tissue, such as myocardium and cardiac vessels. Cells may be delivered systemically or locally and must then proliferate to provide adequate new tissue prior to differentiating into functional cardiomyocytes that couple with the myocardium. Some cells may require significant manipulation prior to implantation. Stem cells may be delivered via infusion into the coronary arteries or injection into the ventricular wall. The mechanism of action of cell therapy for damaged myocardium is not entirely clear and is likely multifactorial.

U.S. Food and Drug Administration (FDA): Cell-Based Therapy for Treatment of Damaged Myocardium

The U.S. Food and Drug Administration (FDA) regulates cells that are processed in commercial laboratories, as well as the surgical devices used to inject the cells into the myocardium. There are several products being commercially developed for the treatment of damaged myocardium. However, the FDA has not yet issued approvals for any technology associated with the transplantation of autologous cells for the treatment of damaged myocardium. Not FDA-Approved products include:

- MyoCell® (US Stem Cell, Inc, Sunrise, FL) is autologous muscle stem cell therapy for the treatment of severe heart damage in heart failure patients.
- MyoCell SDF-1™ (US Stem Cell, Inc, Sunrise, FL) is autologous cell therapy treatment for severe chronic damage in the heart; cells modified to express angiogenic proteins.
- MultiStem® (invimestrocel) (Athersys Inc., Cleveland, OH) is developed from Multipotent Adult Progenitor Cells obtained from healthy adult bone marrow, for the treatment of diseases and conditions in the neurological, inflammatory and immune, cardiovascular disease areas, following hemorrhagic trauma/after severe traumatic injury.
- Ixmyelocel-T (Vericel Corporation, Cambridge, MA) is an expanded, multicellular therapy produced from a patient's own bone marrow (autologous) by selectively expanding two key types of bone marrow mononuclear cells. According to their website, Vericel states that in 2017, the FDA designated the investigation of ixmyelocel-T for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Track Development Program.
- CardiAMP™ Cell Therapy (BioCardia® Inc., Sunnyvale, CA) is designed to be a comprehensive biotherapeutic heart failure solution, incorporating:
 - a proprietary molecular diagnostic to characterize the potency of a patient's own bone marrow cells and determine if they are an optimal candidate for therapy
 - a point of care processing platform to prepare cells at the patient's bedside
 - an optimized therapeutic formulation that builds on the total experience in the cardiac stem cell field to-date
 - a proprietary interventional delivery system that easily navigates a patient's vasculature to securely deliver the specific dosage of cells in a routine cardiac catheterization procedure
- CardiALLO Cell Therapy System (BioCardia® Inc., Sunnyvale, CA) uses culture-expanded, bone marrow-derived mesenchymal stem cells from a universal donor.

Professional Societies/Organizations: Cell-Based Therapy for Treatment of Damaged Myocardium

American College of Cardiology (ACC)/American Heart Association (AHA): The 2023 AHA/ACC Guideline for the Management of Patients With Chronic Coronary Disease noted the following under section 8.2. Evidence Gaps and Areas of Future Research Needs:

- In patients with CCD and refractory angina, research is needed to assess the utility of neuromodulation and thoracic spinal cord stimulation, therapeutic angiogenesis with cell/gene therapies, coronary sinus occlusion, and shockwave therapy.

The 2022 AHA/ACC Guideline for the Management of Heart Failure does not address cell-based therapy (Heidenreich, et al., 2022).

Literature Review: Cell-Based Therapy for Treatment of Damaged Myocardium

Although cell therapy for damaged myocardium is a promising treatment option, randomized controlled trials with large populations and long-term follow-up are necessary to establish the efficacy of these procedures. Studies and professional society opinion are needed to address a number of unresolved, technical issues, including optimum cell type, ideal number of cells, factors that promote engraftment, surgical delivery method and patient selection criteria (Bolli, et al., 2021; Ulus, et al., 2020; 2020, Bartunek, et al., 2020; Sung, et al., 2020; Yau, et al., 2019; Hare, et al., 2017; Patel, et al., 2016; Hamshere, et al., 2015; Heldman, et al., 2014; Vrtovec, et al., 2013; Traverse, et al., 2012; Hare, et al., 2012).

Abouzid et al. (2023) conducted a meta-analysis to assess the safety and efficacy of human umbilical cord-derived mesenchymal stromal cells (HUC-MSCs) therapy versus a placebo in

patients with heart failure and MI. Three RCTs (201 patients) were included in this meta-analysis. There was an improvement in EF in patients who received HUC-MSCs compared to placebo after 12 months of transplantation ($p < 0.00001$). At the six-month follow-up period, there was no significant improvement in EF ($p = 0.43$), indicating that the duration of follow-up can shape the response to therapy. The authors concluded that findings indicate that HUC-MSC transplantation can improve EF but has no meaningful effect on readmission or mortality rates. They noted that existing evidence is insufficient to confirm the efficacy of HUC-MSCs for broader therapeutic applications. Therefore, additional double-blind RCTs with larger sample sizes are required.

Attar et al. (2022) conducted a meta-analysis that investigated the possible long-term clinical efficacy of bone marrow-derived mononuclear cells (BM-MNCs) on major adverse cardiovascular events (MACE) after acute myocardial infarction (AMI). The analysis included 23 randomized trials ($n=2286$ patients; $n=1402$ BM-MNC group, $n=884$ placebo group) that investigated the impact of BM-MNC therapy on clinical outcomes following acute MI. The primary outcomes measured CHF needing hospitalization, reinfarction and mortality with a follow ups ranging from 6–60 months. The secondary outcomes measured LV function with follow ups ranging from 3–12 months. There was a significantly lower risk of hospitalization for CHF and reinfarction in the intervention group compared to the control group ($p=0.005$, $p=0.046$ respectively). Cardiac-related mortality was not significantly different between the two study groups ($p=0.207$). Author noted limitations included heterogeneity across trials including differences in terms of treatment characteristics (cell dosage, cell isolation protocols, storage methods, and image modalities). Secondly, primary outcome of many studies included left ventricular ejection fraction (LVEF) and were not designed to monitor major cardiovascular events. No health disparities were identified by the investigators.

A Cochrane systematic review of 13 randomized controlled trials (RCTs) ($n=762$ [$n=452$ cell therapy and $n=310$ controls]) by Diaz-Navarro et al. (2021) assessed the effectiveness and safety of stem cell transplant in adults with non-ischemic dilated cardiomyopathy (DCM). The RCTs included compared the infusion of bone marrow-derived stem cells into the heart muscle with the usual-care (control) treatment in people diagnosed with DCM. Studies were classified and analyzed into three categories according to the comparison intervention, which consisted of no intervention/placebo, cell mobilization with cytokines, or a different mode of SCT. The studies included an average of 60 people aged 45 to 58.5 years and 50%–89% men in each trial. Following therapy, the participants were assessed from six months to five years, with most studies at one year. The outcomes measured all-cause mortality, safety, health-related quality of life (HRQoL), performance status and major adverse cardiovascular events. The evidence reviewed was considered low to very low quality due to the small number of events, the results were not similar across studies, risk of bias and issues with study design. The study reported that there is uncertainty regarding mortality, procedural complications, health-related quality of life and exercise capacity when comparing SCT to the control. Low-quality evidence suggested that SCT may slightly improve deterioration of heart function and may not increase the risk of abnormal heartbeats in people with DCM. There were not any studies that reported other relevant outcomes such as major cardiac adverse events. When comparing SCT plus cytokine to control there is uncertainty regarding mortality. SCT plus cytokine may not improve health-related quality of life but may improve exercise capacity as well as some physiological measures related to cardiac function (it is unclear the extent and clinical benefits for patients). No studies reported major cardiac adverse events or abnormal heartbeats. The authors concluded based on low quality evidence that more research is needed to establish the role of SCT in the treatment of DCM and the most effective therapies. No health disparities were identified by the investigators, however there were more males enrolled than females.

Yang et al. (2020) conducted a systematic review and meta-analysis of the evidence ($n=43$ RCTs) evaluating the short and long-term efficacy of mononuclear cell transplantation (MNC) in patients with myocardial infarction. The primary outcomes measured the changes in left ventricular

ejection fraction (LVEF) and infarct size from baseline to follow-up. Secondary outcomes measured changes in the left ventricular end-systolic volume, left ventricular end-diastolic volume, brain natriuretic peptide/N-terminal pro-B-type natriuretic peptide, 6-minute walk test, New York Heart Association class, and major adverse cardiac events (MACE). Randomized controlled trials (RCTs) were eligible for inclusion if the transplanted cells were limited to unsorted MNC cell types without using pretreated or engineered MNCs; the patients had ST-segment elevation myocardial infarction (STEMI) and ischemic cardiomyopathy (ICM) with previous MI; and more than one month of follow-up was recorded. The follow-up ranged from 3–96 months. In the short-term follow-up, patients treated with MNCs demonstrated a significant increase in absolute LVEF of 2.21% ($p < 0.001$) and 6.01% ($p < 0.001$) in acute myocardial infarction (AMI) and ischemic cardiomyopathy studies, respectively. This effect was sustained in long-term follow-up. MNC therapy significantly reduced left ventricular end-systolic volume; however, infarct size, 6-minute walk test, New York Heart Association class, and MACE rates were comparable. Author noted limitations included the clinical heterogeneity across trials, particularly with regard to cell dosage, the timing of infusion, and imaging modalities. Another limitation was the small number of patients that were available for analysis of performance status and functional biomarkers. The authors concluded that MNC therapy may convey a modest but sustained increase in LVEF in ischemic cardiomyopathy patients. Well-designed, adequately powered RCTs using optimized delivery and doses are needed to support the outcome of this study.

Cell-Based Therapy for Peripheral Arterial Disease

An advanced form of Peripheral Arterial Disease (PAD) known as chronic limb-threatening ischemia is associated with gangrene formation, ulceration, and amputation of the limb. Surgical and endovascular interventions to restore vascularization to the ischemic limb are effective but not suitable for all patients with PAD. A promising approach to induce revascularization is therapeutic angiogenesis, which aims to induce the formation of new blood vessels from preexisting ones. Numerous strategies to augment therapeutic angiogenesis have been tested in clinical studies, including cell, protein, and gene therapies, although the results have only shown minimal-to-moderate therapeutic benefit. Some of the limitations of the cell-based strategies include poor transplant cell survival, short-lived gene/protein delivery, harsh inflammatory host response, and suboptimal therapeutic dosing or frequency. Therapeutic cells that have been tested in clinical trials of PAD include bone marrow-derived mononuclear cells, mesenchymal stromal cells (MSCs), and subpopulations within these cell types based on surface antigen expression. Considering the variable approaches used by different groups, the wide range of cell types used, and the absence of standardized protocols for characterization of the cells and for evaluation of clinical outcome, there is substantial uncertainty regarding the effectiveness of various cell types in PAD patients (Huang, et al., 2024; Frangogiannis, et al., 2019).

U.S. Food and Drug Administration (FDA): Cell-Based Therapy for Treatment of Peripheral Arterial Disease

- SmartPREP2 Centrifuge System (Harvest Technologies Corp, Inc. Plymouth, MA) received 510(k) approval on January 13, 2016 (K103340). The SmartPREP2 Centrifuge System is intended to be used in the clinical laboratory or intraoperatively at point-of-care for the safe and rapid preparation of platelet poor plasma and platelet concentrate from a small sample of blood and for
- preparation of a cell concentrate from bone marrow. Clinical trial NCT00595257 was a clinical trial using the SmartPREP2 BMAC System that assessed the use of autologous bone marrow aspirate concentrate (BMAC) for the treatment of non-reconstructable critical limb ischemia due to peripheral arterial occlusive disease.
- MarrowStim PAD Kit™ (Zimmer Biomet, Warsaw, Ind) is an investigational device (Wang, et al., 2017).
- Pluristem cell therapy product, PLX-PAD, is for the treatment of critical limb ischemia (CLI). PLX-PAD cell treatment (Pluri Biotech Ltd. [Israel] previously Pluristem Therapeutics, Inc.)

(Pluristem) is not FDA-approved. The company's website states that on January 9, 2018, the U.S. Food & Drug Administration (FDA) cleared the company's Expanded Access Program (EAP) for the use of its PLX-PAD cell treatment in patients with Critical Limb Ischemia (CLI). EAP allows the use of an investigational medical product outside of clinical trials and is usually granted in cases where patients are unsuitable for inclusion under the study protocol and the patient's condition is life-threatening with an unmet medical need. (See NCT03006770, Norgren, et al., 2024).

- Ixmyelocel-T (Vericel Corporation, Cambridge, MA) is not FDA-approved. It is an expanded, multicellular therapy produced from a patient's own bone marrow (autologous) by selectively expanding two key types of bone marrow mononuclear cells (See Powell, et al., 2012).

Professional Societies/Organizations: Cell-Based Therapy for Treatment of Peripheral Arterial Disease

American Heart Association (AHA)/American College of Cardiology (ACC): The use of cell therapy is not mentioned in the 2018 Appropriate Use Criteria for Peripheral Artery Intervention document (Bailey, et al., 2019) or in the 2016 AHA/ACC guidelines on the management of patients with lower peripheral artery disease (Gerhard-Herman, et al., 2017).

Literature Review: Cell-Based Therapy for Treatment of Peripheral Arterial Disease

Despite extensive research, robust clinical evidence supporting the use of cell therapy in patients with critical limb ischemia is lacking. Randomized controlled clinical trial results are mixed. Considering the variable approaches used by different groups, the wide range of cell types used, and the absence of standardized protocols for characterization of the cells and for evaluation of clinical outcome, there is substantial uncertainty regarding the effectiveness of various cell types in PAD patients. There is a need for high-quality clinical studies to test the effectiveness of cell therapy in PAD patients. Moreover, studies are needed to identify the optimal selection criteria for treatment candidate, optimal cell types, method of administration, and to develop strategies that may enhance homing, survival and effectiveness of the injected cells (Sharma, et al., 202; Lindeman, et al., 2018; Perin, et al., 2017; Teraa, et al., 2015; Gupta, et al., 2013).

In 2022 Moazzami et al. published an updated Cochrane review evaluating local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischemia that was initially published in 2011. Four randomized controlled trials (RCTs), with a combined total of 176 patients, met the inclusion criteria. Participants were randomized to receive either intramuscular cell implantation of bone marrow mononuclear cells (BMMNCs) or control. The control groups varied between studies, and included conventional therapy, diluted autologous peripheral blood, and saline. Three studies (n=123) reported there was no clear evidence that the administration of BMMNCs had an effect on mortality when compared to the control (very low-certainty evidence). All trials assessed changes in pain severity, but the trials used different forms of pain assessment tools, therefore the data was unable to be pooled. Three studies individually reported that there were not any differences in pain reduction between the groups and one study reported that pain reduction was greater in the BMMNC group compared to the control group (very low-certainty evidence). All four trials reported the rate of amputation at the end of the study period. However, the authors are uncertain if amputations were reduced in the BMMNC group compared to the control group because the potential benefit was lost when the concerning data was removed from the analysis. Ankle-brachial index was reported differently by each study, so data was not able to be pooled. Three studies reported no changes between groups, and one study reported greater improvement in ABI in the BMMNC group compared to the control group (very low-certainty evidence). One study reported pain-free walking distance, finding no clear difference between the groups (low-certainty evidence). Lastly, the data was pooled for the side effects reported during the follow-up, which did not show any clear difference between the groups (very low-certainty evidence). The review was unable to draw conclusions to support the use of local intramuscular

transplantation of BMMNC for improving clinical outcomes in people with CLI due to the very low-to low-certainty evidence and limited data. Evidence from larger RCTs are needed in order to provide adequate statistical power to assess the role of this procedure. No health disparities were identified by the investigators.

Pu et al. (2022) conducted a meta-analysis of randomized controlled trials that assessed the safety and efficacy of autologous stem cell therapy in patients with atherosclerosis obliterans (ASO). Twelve RCTs (n=630 patients) met inclusion criteria. The criteria included: RCT trial design, a diagnosis of limb ischemia with ASO, the intervention group received autologous cell implantation, and the control group received placebo administration or standard care. The primary outcome measured the total amputation rate. There were ten RCTs (n=610 participants) that reported total amputation during the study follow-up period. The results showed that cell therapy significantly improved total amputation ($p=0.004$). Secondary outcomes measured major amputation, mortality, perfusion index and symptom (ABI, TcO₂, rest pain score, and ulcer size). There were eight RCTs (n=485 participants) that showed cell therapy significantly reduced major amputation ($p=0.02$), significantly improved perfusion index ($p=0.004$) and significantly decreased rest pain score ($p=0.007$) when compared to placebo or standard care. In contrast, the results indicated that no significant difference was found between cell therapy and control groups regarding all-cause mortality ($p=0.34$) and reduction of ulcer size ($p=0.39$). Limitations noted by the authors included the small patient population, small amount of data and that most trials were designed for "no option" patients and results are not generalizable to all patients with PAD. Additionally, the studies in subgroup analyses were too small and the results should be interpreted with caution. Lastly, the heterogeneity of the included trials was inevitable due to the diversity of source and dosage of cell products, route of administration, follow-up duration, the severity of limb ischemia, and treatments in the control group. Additional RCT's with a larger sample size and a defined treatment design are needed. No health disparities were identified by the investigators.

Gao et al. (2019) conducted a systematic review and meta-analysis that evaluated the efficacy and safety of autologous implantation of stem cells for peripheral artery disease. The primary outcomes measured amputation rate, major amputation rate, ulcer healing rate, and side effects. The second outcomes measured were ankle-brachial index (ABI), transcutaneous oxygen tension (TcO₂), rest pain score, and pain-free walking distance (PFWD). The review consisted of 27 RCTs (n=1186 patients) with 1280 limbs. Meta-analysis indicated that autologous stem cell therapy was more effective than conventional therapy on the healing rate of ulcers. There was also significant improvement in ABI, TcO₂, and PFWD while significant reduction was shown in amputation rate and rest pain scores. But the result presented no significant improvement in major limb salvage. Eight trials reported the side effects of autologous stem cell therapy, and no serious side effects related to stem cells were reported. Author noted limitations included low quality studies with unclear or high risk of bias. Secondly, several studies had a small patient population with limited information for outcomes, such as adverse events. Thirdly, the included patients, types of stem cells, methods of transplantation, control group, and follow-up time were different among RCTs, which could cause heterogeneity. The author concluded that autologous stem cell therapy may have a positive effect on "no-option" patients with PAD, but presented no significant improvement in major limb salvage. The evidence is insufficient to due to high risk of bias and low-quality evidence of outcomes. Larger, randomized, double-blind, placebo-controlled, and multicenter trials are needed.

Abdul Wahid et al. (2018) conducted a Cochrane systematic review to compare the efficacy and safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for the treatment of 'no-option' critical lower limb ischemia (CLI) patients. The trial included 7 randomized controlled trials (359 participants) that compared bone marrow-mononuclear cells (BM-MNCs) versus mobilized peripheral blood stem cells (mPBSCs), BM-MNCs versus bone marrow-mesenchymal stem cells

(BM-MSCs), high cell dose versus low cell dose, and intramuscular (IM) versus intra-arterial (IA) routes of cell implantation. The authors concluded that based on low- and very low-quality evidence there are no clear differences between different stem cell sources and different treatment regimens of autologous cell implantation for outcomes such as all-cause mortality, amputation rate, ulcer healing, and rest pain for 'no option' CLI patients. Do to the lack of high-quality evidence the efficacy and long-term safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for the treatment of 'no-option' CLI patients, cannot be determined. RCTs with larger numbers of participants and longer follow-up are needed to determine the efficacy and safety of cell-based therapy for CLI patients.

Xie et al. (2018) conducted a systematic review and meta-analysis of 23 randomized controlled trials (n=962 patients) to review evidence for the safety and efficacy of autologous stem cell therapy in critical limb ischemia (CLI). The included patients were ineligible for surgical or percutaneous revascularization. The studies included the following types of stem cells: bone marrow mononuclear cells, bone marrow mesenchymal stem cells, bone marrow stem cells, peripheral blood mononuclear cells, peripheral blood stem cells, CD34+, or CD133+ stem cells. The transplantation method of stem cell was intramuscular or intra-arterial. The mean follow-ups of the studies were three months, six months and 12 months. Meta-analysis showed that cell therapy significantly increased the probability of ulcer healing, angiogenesis and reduced the amputation rates ($p < 0.00001$, $p < 0.0001$, and $p < 0.0001$, respectively) compared to the control group. Ankle-brachial index (ABI) and pain-free walking distance were significantly better in the cell therapy group than in the control group ($p < 0.01$). The authors concluded that autologous stem cell therapy is safe and effective in CLI. However, higher quality and larger RCTs are required for further investigation to support clinical application of stem cell transplantation.

Rigato et al. (2017) performed a systematic review and meta-analysis to evaluate the safety and effectiveness of autologous cell therapy for intractable peripheral arterial disease (PAD)/critical limb ischemia (CLI). RCTs (19 studies/837 patients), non-randomized trials (n=7 studies/338 patients), and non-controlled studies (n=41 studies/1177 patients) were included in the analysis. Patients selected in studies were ineligible for surgical or percutaneous revascularization. The cell products used in studies included BMMNCs, BMMSCs, or PBMNCs. The primary outcome was the rate of major amputation (defined as the removal of the limb of a part of it above the ankle) in the cell therapy versus control group. Secondary outcomes included amputation free survival and complete wound healing. Follow-up timeframes ranged from six to ten months. A primary meta-analysis was performed on all RCTs (n=19 studies). For the primary outcome, cell therapy was associated with a statistically significant reduction in amputation rate ($p = 0.0004$) and increased probability of amputation-free survival ($p = 0.01$). Mortality was not significantly improved ($p = 0.39$). Cell therapy increased the probability of complete wound healing by 59%. In a sub-analysis of only randomized placebo-controlled trials (n=11 studies), cell therapy was associated with non-significant improvements in amputation rate ($p = 0.12$), amputation-free survival ($p = 0.36$), and wound healing ($p = 0.07$). When the analysis was further limited to RCTs with a low risk of bias ($n \leq 3$ studies depending on the outcome), cell therapy appeared to confer no benefit for all endpoints. In general cell therapy was found to be associated with mild and primarily transient adverse events. The secondary analysis (i.e., all controlled trials; n=1175 patients) showed that approximately one amputation per year could potentially be avoided for every two patients successfully treated with cell therapy. Although the overall results of this analysis suggest that cell therapy may be safe and effective in treating this subset of patients with PAD/CLI, the validity is challenged by limitations of low-moderate quality and high heterogeneity of studies. Additional well designed RCTs with long-term follow-up are needed to confirm these findings.

Medicare Coverage Determinations

	Contractor	Determination Name/Number	Revision Effective Date
NCD	National	Cellular Therapy (30.8)	'Long standing'
LCD		No Determination found	

Note: Please review the current Medicare Policy for the most up-to-date information.
(NCD = National Coverage Determination; LCD = Local Coverage Determination)

Coding Information

Notes:

1. This list of codes may not be all-inclusive since the American Medical Association (AMA) and Centers for Medicare & Medicaid Services (CMS) code updates may occur more frequently than policy updates.
2. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Considered Experimental/Investigational/Unproven when used to report transplantation of cells into the myocardium:

CPT®* Codes	Description
33999	Unlisted procedure, cardiac surgery
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38232	Bone marrow harvesting for transplantation; autologous
93799	Unlisted cardiovascular service or procedure

HCPCS Codes	Description
C9782	Blinded procedure for New York Heart Association (NYHA) Class II or III heart failure, or Canadian Cardiovascular Society (CCS) Class III or IV chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (e.g., transthoracic echocardiography, ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post-transplant care in the global definition

Considered Not Medically Necessary when used to report autologous intra-arterial or intra-muscular bone marrow cell transplantation for peripheral arterial disease and other occlusive conditions:

CPT®* Codes	Description
37799	Unlisted procedure, vascular surgery
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38232	Bone marrow harvesting for transplantation; autologous
0263T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest
0264T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest
0265T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy

***Current Procedural Terminology (CPT®) ©2023 American Medical Association: Chicago, IL.**

References

1. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA, et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med. 2007 May 28;167(10):989-97.
2. Abdul Wahid SF, Ismail NA, Wan Jamaludin WF, Muhamad NA, Abdul Hamid MKA, Harunarashid H, et al. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients. Cochrane Database Syst Rev. 2018 Aug 29;8(8):CD010747.
3. Abouzid MR, Ali K, Kamel I, Esteghamati S, Saleh A, Ghanim M. The Safety and Efficacy of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Patients With Heart Failure and Myocardial Infarction: A Meta-Analysis of Clinical Trials. Cureus. 2023 Nov 29;15(11):e49645.
4. Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rev Esp Cardiol (Engl Ed). 2018 Feb;71(2):111.
5. Athersys, Inc. MultiStem. Accessed March 2024. Available at URL address: <https://www.athersys.com/multistem-therapy/overview/default.aspx>
6. Attar A, Hosseinpour A, Hosseinpour H, Kazemi A. Major cardiovascular events after bone marrow mononuclear cell transplantation following acute myocardial infarction: an updated post-BAMI meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2022 Jun 9;22(1):259.

7. Bailey SR, Beckman JA, Dao TD, Misra S, Sobieszczyk PS, et al. ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. *J Am Coll Cardiol*. 2019 Jan 22;73(2):214-237.
8. Bartunek J, Terzic A, Davison BA, Behfar A, Sanz-Ruiz R, Wojakowski W, et al. Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. *ESC Heart Fail*. 2020 Oct 23;7(6):3345-54.
9. BioCardia®, Inc. CardiAMP™ Cell Therapy. Accessed March 2024. Available at URL address: <https://www.biocardia.com/pipeline/cardiamp-cell-therapy/id/8>
10. BioCardia®, Inc. CardiALLO Cell Therapy System. Accessed March 2024. Available at URL address: <https://www.biocardia.com/pipeline/cardiallo-cell-therapy/id/1002>
11. Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, et al. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRn CONCERT-HF trial. *Eur J Heart Fail*. 2021 Apr;23(4):661-674.
12. Centers for Medicare and Medicaid Services (CMS). National Coverage Determinations (NCDs) alphabetical index. Accessed March 2024. Available at URL address: <https://www.cms.gov/medicare-coverage-database/indexes/ncd-alphabetical-index.aspx>
13. Diaz-Navarro R, Urrútia G, Cleland JG, Poloni D, Villagran F, Acosta-Dighero R, Bangdiwala SI, Rada G, Madrid E. Stem cell therapy for dilated cardiomyopathy. *Cochrane Database Syst Rev*. 2021 Jul 21;7(7):CD013433.
14. Frangogiannis NG. Cell therapy for peripheral artery disease. *Curr Opin Pharmacol*. 2018 Apr;39:27-34.
15. Gao W, Chen D, Liu G, Ran X. Autologous stem cell therapy for peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. *Stem Cell Res Ther*. 2019 May 21;10(1):140.
16. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2017 Mar 21;69(11):e71-e126
17. Gupta PK, Chullikana A, Parakh R, Desai S, Das A, Gottipamula S, et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. *J Transl Med*. 2013 Jun 10;11:143.
18. Hamshere S, Arnous S, Choudhury T, Choudry F, Mozid A, Yeo C, et al. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial. *Eur Heart J*. 2015 Nov 21;36(44):3061-9.

19. Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, et al. Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy: POSEIDON-DCM Trial. *J Am Coll Cardiol*. 2017 Feb 7;69(5):526-537.
20. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *JAMA*. 2012 Dec 12;308(22):2369-79.
21. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1. Erratum in: *Circulation*. 2022 May 3;145(18):e1033. Erratum in: *Circulation*. 2022 Sep 27;146(13):e185.
22. Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. *JAMA*. 2014 Jan 1;311(1):62-73.
23. Huang NF, Stern B, Oropeza BP, Zaitseva TS, Paukshto MV, Zoldan J. Bioengineering Cell Therapy for Treatment of Peripheral Artery Disease. *Arterioscler Thromb Vasc Biol*. 2024 Mar;44(3):e66-e81.
24. Liew LC, Ho BX, Soh BS. Mending a broken heart: current strategies and limitations of cell-based therapy. *Stem Cell Res Ther*. 2020 Mar 26;11(1):138.
25. Lindeman JHN, Zwaginga JJ, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ, et al. No Clinical Benefit of Intramuscular Delivery of Bone Marrow-derived Mononuclear Cells in Nonreconstructable Peripheral Arterial Disease: Results of a Phase-III Randomized-controlled Trial. *Ann Surg*. 2018 Nov;268(5):756-761.
26. Moazzami B, Mohammadpour Z, Zabala ZE, Farokhi E, Roohi A, Dolmatova E, et al. Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb ischaemia. *Cochrane Database Syst Rev*. 2022 Jul 8;7(7):CD008347.
27. Norgren L, Weiss N, Nikol S, Lantis JC, Patel MR, Hinchliffe RJ, et al. PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial. *Br J Surg*. 2024 Jan 31;111(2):znad437.
28. Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD; ixCELL-DCM Investigators. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. *Lancet*. 2016 Jun 11;387(10036):2412-21.
29. Pepine CJ, Raval AN. The CardiAMP Cell Therapy for Heart Failure trial. *Tex Heart Inst J*. 2023 Oct 23;50(5):e238242.
30. Perin EC, Murphy MP, March KL, Bolli R, Loughran J, Yang PC, et al. Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN Patients with Intermittent Claudication Injected with ALDH Bright Cells (PACE) Trial. *Circulation*. 2017 Feb 16.

31. Pluri-Biotech. Pluristem. PLX_PAD. Accessed March 2024. Available at URL address: https://pluri-biotech.com/wp-content/uploads/2023/01/Expanded_Access_Program_CLI_final_isa.pdf
32. Poole J, Mavromatis K, Binongo JN, Khan A, Li Q, Khayata M, Rocco E, Topel M, et al. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial. *JAMA*. 2013 Dec 25;310(24):2631-9.
33. Powell RJ, Marston WA, Berceli SA, Guzman R, Henry TD, et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: the randomized, double-blind, placebo-controlled RESTORE-CLI trial. *Mol Ther*. 2012 Jun;20(6):1280-6.
34. Pu H, Huang Q, Zhang X, Wu Z, Qiu P, Jiang Y, et al. A meta-analysis of randomized controlled trials on therapeutic efficacy and safety of autologous cell therapy for atherosclerosis obliterans. *J Vasc Surg*. 2022 Apr;75(4):1440-1449.e5.
35. Rigato M, Monami M, Fadini GP. Autologous Cell Therapy for Peripheral Arterial Disease: Systematic Review and Meta-Analysis of Randomized, Nonrandomized, and Noncontrolled Studies. *Circ Res*. 2017 Apr 14;120(8):1326-1340.
36. Sung PH, Li YC, Lee MS, Hsiao HY, Ma MC, Pei SN, et al. Intracoronary Injection of Autologous CD34+ Cells Improves One-Year Left Ventricular Systolic Function in Patients with Diffuse Coronary Artery Disease and Preserved Cardiac Performance-A Randomized, Open-Label, Controlled Phase II Clinical Trial. *J Clin Med*. 2020 Apr 7;9(4):1043.
37. Teraa M, Sprengers RW, Schutgens RE, Slaper-Cortenbach IC, van der Graaf Y, Algra A, et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. *Circulation*. 2015 Mar 10;131(10):851-60.
38. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, et al.; Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the Late TIME randomized trial. *JAMA*. 2011 Nov 16;306(19):2110-9.
39. Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, et al. Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. *JAMA* 2012 Dec 12;308(22):2380-9.
40. Ulus AT, Mungan C, Kurtoglu M, Celikkan FT, Akyol M, Sucu M, et al. Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial). *Int J Stem Cells*. 2020 Nov 30;13(3):364-376.
41. U.S. Food and Drug Administration. 510(k) approval. SmartPReP2 Centrifuge System (Harvest Technologies Corp, Inc. Plymouth, MA). K103340. January 13, 2016. Accessed March 2024. Available at URL address: https://www.accessdata.fda.gov/cdrh_docs/pdf10/K103340.pdf

42. U.S. Food and Drug Administration. Regenerative Medicine Advanced Therapy (RMAT) Designation. Current as of 07/21/2023. Accessed March 2024. Available at URL address: <https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm>
43. U.S. Stem Cell, Inc. Products. Accessed March 2024. Available at URL address: <https://us-stemcell.com/products/>
44. Vericel Corporation. Investor Relations. News releases. Accessed March 2024. Available at URL address: <https://investors.vcel.com/news-releases/news-release-details/vericel-receives-fda-fast-track-designation-ixmyelocel-t>
45. Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, et al. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. *Circ Res.* 2013 Jan 4;112(1):165-73.
46. Vrtovec B, Poglajen G, Sever M, Zemljic G, Frljak S, Cerar A, et al. Effects of Repetitive Transendocardial CD34+ Cell Transplantation in Patients With Nonischemic Dilated Cardiomyopathy. *Circ Res.* 2018 Jul 20;123(3):389-396.
47. Wang SK, Green LA, Motaganahalli RL, Wilson MG, Fajardo A, Murphy MP. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia. *J Vasc Surg.* 2017 Jun;65(6):1850-1857.e2.
48. Writing Committee Members; Virani SS, Newby LK, Arnold SV, Bittner V, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2023 Aug 29;82(9):833-955.
49. Xie B, Luo H, Zhang Y, Wang Q, Zhou C, Xu D. Autologous Stem Cell Therapy in Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Trials. *Stem Cells Int.* 2018 May 24;2018:7528464.
50. Yang D, O'Brien CG, Ikeda G, Traverse JH, Taylor DA, Henry TD, et al. Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction. *Am Heart J.* 2020;220:155-175.
51. Yau TM, Pagani FD, Mancini DM, Chang HL, Lala A, Woo YJ, et al. Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. *JAMA.* 2019 Mar 26;321(12):1176-1186.

Revision Details

Type of Revision	Summary of Changes	Date
Annual Review	<ul style="list-style-type: none"> • No clinical policy statement changes. 	5/15/2024

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.